IMVT - Company ID 0001764013
The table below shows Immunovant, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $1.13M | $2.08M | $5.34M | $700.00K | $12.23M | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $948.82M |
| $767.66M |
| $665.77M |
| $404.33M |
| $512.93M |
| $409.01M |
| Property, plant & equipment | $443.00K | $844.00K | $462.00K | $333.00K | $330.00K | $201.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $957.01M | $776.22M | $666.37M | $405.84M | $515.56M | $412.49M |
| Accounts payable | $7.54M | $17.66M | $7.16M | $1.35M | $18.63M | $2.43M |
| Total current liabilities | $104.42M | $68.78M | $48.61M | $43.30M | $44.52M | $18.77M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $104.42M | $68.78M | $48.61M | $43.34M | $45.74M | $21.01M |
| Retained earnings | -$1.75B | -$1.24B | -$825.68M | -$566.35M | -$355.39M | -$198.66M |
| Total equity | $852.59M | $707.45M | $617.76M | $362.49M | $469.82M | $391.48M |